The pre-specified exploratory OS analyses were conducted in the intention-to-treat (ITT) population (stage IB-IIIA), in stage II-IIIA and in patients with stage II-IIIA NSCLC with PD-L1 ≥ 1%: a greater benefit was observed in patients with stage II-IIIA disease and PD-L1 ≥ 1%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.